Poland Launches Phase 2 Study for COVID-19 Oral Treatment

Cyxone announced it has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate COVID-19 patients. The oral treatment is intended to prevent the progression to acute respiratory distress symptoms caused by virus-related overactivation of the immune system.

Preliminary results are expected in the third quarter of 2021.

"Given a successful outcome, Rabeximod could be developed as a candidate drug not only for COVID-19 but for the treatment of other disorders of the immune system including virally induced acute respiratory disorders", commented CEO Tara Heitner, in a press statement.